IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Guillaud Bataille, Marine ^a,b   Ragazzon, Bruno ^c   De Reyniès, Aurélien ^d   Chevalier, Claire ^a   Francillard, Isabelle ^a,b   Barreau, Olivia ^b,c   Steunou, Virginie ^e,f   Guillemot, Johann ^a   Tissier, Frédérique ^c,g   Rizk Rabin, Marthe ^c   René Corail, Fernande ^c   Al Ghuzlan, Abir ^h   Assié, Guillaume ^b,c   Bertagna, Xavier ^b,c   Baudin, Eric ^h   Le Bouc, Yves ^e,f   Bertherat, Jérôme ^b,c   Clauser, Eric ^a,b  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b Institut Cochin   (France)

^c INSTITUT COCHIN   (France)

^d Cartes d'Identité des Tumeurs Program Ligue Nationale Contre le Cancer   (France)

^e INSERM   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 9; PLATELET DERIVED GROWTH FACTOR A; PROTEIN TYROSINE KINASE; SOMATOMEDIN B; MESSENGER RNA;

ADRENAL CORTEX CARCINOMA; ADRENOCORTICAL CARCINOMA CELL LINE; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHROMOSOME 11P; CONTROLLED STUDY; EPIGENETICS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF2 GENE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TUMOR GROWTH; UNIPARENTAL DISOMY; VERY ELDERLY; ADOLESCENT; CELL PROLIFERATION; CHROMOSOME 11; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENETICS; GENOME IMPRINTING; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 11; DNA METHYLATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC LOCI; GENOMIC IMPRINTING; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84905457098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103744     Document Type: Article

References (46)

1. De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1: 769-783. (Pubitemid 37361561)
2. Harris LK, Westwood M (2012) Biology and significance of signalling pathways activated by IGF-II. Growth Factors 30: 1-12.
3. Gourmelen M, Perin L, Le Bouc Y (1994) IGFs and their binding proteins. Nucl Med Biol 21: 297-302. (Pubitemid 24119847)
4. Callan AC, Milne E (2009) Involvement of the IGF system in fetal growth and childhood cancer: an overview of potential mechanisms. Cancer Causes Control 20: 1783-1798.
5. Zhan S, Shapiro DN, Helman LJ (1994) Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94: 445-448. (Pubitemid 24218124)
6. El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, et al. (1989) Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest 84: 829-839. (Pubitemid 19228354)
7. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, et al. (1988) Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48: 6844-6849. (Pubitemid 19012216)
8. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, et al. (1986) Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 46: 6169-6173. (Pubitemid 17221751)
9. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, et al. (1994) Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78: 1444-1453. (Pubitemid 24181019)
10. Ribeiro TC, Latronico AC (2012) Insulin-like growth factor system on adrenocortical tumorigenesis. Mol Cell Endocrinol 351: 96-100.
11. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195-1201. (Pubitemid 20137851)
12. Else T, Kim A, Sabolch A, Raymond V, Kandathil A, et al. (2013) Adrenocortical carcinoma. Endocrine reviews: er20131029.
13. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83: 1713-1720. (Pubitemid 28501047)
14. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, et al. (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61: 6762-6767. (Pubitemid 32896498)
15. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, et al. (1997) Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82: 2559-2565. (Pubitemid 27337873)
16. Logie A, Boulle N, Gaston V, Perin L, Boudou P, et al. (1999) Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol 23: 23-32. (Pubitemid 29369556)
17. Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, et al. (2008) Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocrine-related cancer 15: 623-634. (Pubitemid 351880848)
18. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, et al. (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94: 204-212.
19. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, et al. (2008) Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 93: 3524-3531.
20. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, et al. (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90: 1819-1829. (Pubitemid 40464057)
21. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, et al. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108-1115.
22. Giordano TJ (2003) Gene expression profiling of endocrine tumors using DNA microarrays: progress and promise. Endocr Pathol 14: 107-116.
23. Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, et al. (2005) Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138: 1087-1094. (Pubitemid 41797349)
24. Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, et al. (2012) Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS One 7: e44171.
25. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, et al. (2012) Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and beta-catenin. Am J Pathol 181: 1017-1033.
26. Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13: 202-206. (Pubitemid 19081702)
27. Libe R, Groussin L, Tissier F, Elie C, Rene-Corail F, et al. (2007) Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 13: 844-850. (Pubitemid 46340358)
28. Groussin L, Massias JF, Bertagna X, Bertherat J (2000) Loss of expression of the ubiquitous transcription factor cAMP response element-binding protein (CREB) and compensatory overexpression of the activator CREMtau in the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 85: 345-354. (Pubitemid 32268836)
29. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, et al. (2007) Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol 21: 2968-2987. (Pubitemid 350223508)
30. Ragazzon B, Lefrancois-Martinez AM, Val P, Sahut-Barnola I, Tournaire C, et al. (2006) Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis. Endocrinology 147: 1805-1818.
31. Azzi S, Rossignol S, Steunou V, Sas T, Thibaud N, et al. (2009) Multilocus methylation analysis in a large cohort of 11p15-related foetal growth disorders (Russell Silver and Beckwith Wiedemann syndromes) reveals simultaneous loss of methylation at paternal and maternal imprinted loci. Human molecular genetics 18: 4724-4733.
32. Azzi S, Steunou V, Rousseau A, Rossignol S, Thibaud N, et al. (2011) Allele-specific methylated multiplex real-time quantitative PCR (ASMM RTQ-PCR), a powerful method for diagnosing loss of imprinting of the 11p15 region in Russell Silver and Beckwith Wiedemann syndromes. Human mutation 32: 249-258.
33. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, et al. (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115: 243-250.
34. Gicquel C, Le Bouc Y (1997) Molecular markers for malignancy in adrenocortical tumors. Horm Res 47: 269-272. (Pubitemid 27196464)
35. Shen W, Xian J, Hu WL, Liu J, Liu J (2007) [Effect of insulin-like growth factor and its receptor-I antibody on growth of human adrenocortical carcinoma SW-13 cell lines in vitro]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 27: 88-91.
36. Weber MM, Fottner C, Wolf E (2000) The role of the insulin-like growth factor system in adrenocortical tumourigenesis. European journal of clinical investigation 30 Suppl 3: 69-75. (Pubitemid 32154554)
37. Figueiredo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovsky MA, et al. (1999) Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 84: 1116-1121. (Pubitemid 29138252)
38. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, et al. (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67: 600-608. (Pubitemid 46192198)
39. Kamio T, Shigematsu K, Kawai K, Tsuchiyama H (1991) Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 138: 83-91.
40. Weber MM, Auernhammer CJ, Kiess W, Engelhardt D (1997) Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 136: 296-303. (Pubitemid 27130054)
41. Leboulleux S, Gaston V, Boulle N, Le Bouc Y, Gicquel C (2001) Loss of heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor locus: a frequent but late event in adrenocortical tumorigenesis. Eur J Endocrinol 144: 163-168. (Pubitemid 32181687)
42. Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, et al. (2005) AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors. J Clin Endocrinol Metab 90: 4366-4370. (Pubitemid 41058221)
43. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
44. Kaneda A, Wang CJ, Cheong R, Timp W, Onyango P, et al. (2007) Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci U S A 104: 20926-20931.
45. Edgren M, Eriksson B, Wilander E, Westlin JE, Nilsson S, et al. (1997) Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 17: 1303-1309. (Pubitemid 27182456)
46. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, et al. (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65: 765-773.